文献速递其他结缔组织病

特发性炎性肌病患者与医生对疾病活动度评估不一致的纵向分析

Patient-physician discordance in idiopathic inflammatory myopathies: a longitudinal analysis of links to disease activity and damage.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

本研究基于MyoCite IIM队列,分析患者与医生全球评估(PGA与PhGA)不一致的模式及纵向轨迹。基线临床显著不一致发生率为19.3%,以正向不一致(PGA>PhGA)为主(16.8%)。基线正向不一致预测1年功能能力较差,且不一致通过未管理的疼痛单向驱动未来功能残疾。

要点

  • 基线临床显著不一致发生率为19.3%,以正向不一致(PGA>PhGA)为主(16.8%)。
  • 基线正向不一致强烈预测1年功能能力(HAQ)较差(P=0.034)。
  • 不一致通过疼痛单向驱动未来功能残疾(32.1%中介,P<0.001)。

核心结论

  • 患者与医生评估不一致是特发性炎性肌病未来功能丧失的上游驱动因素,而非仅仅是现有客观损害的反映。
  • 疼痛显著中介了不一致对未来功能残疾的影响,反向中介不显著。

研究设计与样本

  • 基于MyoCite IIM队列的纵向分析,基线样本量244例,纵向随访6、12、24个月样本量128例。
  • 不一致定义为患者与医生全球评估(0-10 cm量表)差值≥±1 cm。
  • 采用线性混合效应模型(n=191)和双向中介模型识别独立驱动因素和因果路径。

主要发现

  • 基线临床显著不一致发生率为19.3%,正向不一致(PGA>PhGA)为16.8%,见于DM、PM、重叠肌炎、抗合成酶综合征等亚型。
  • 24个月内不一致随治疗缩小。
  • 基线正向不一致强烈预测1年功能能力(HAQ)较差(P=0.034)。
  • 客观肌无力统计上驱动差距(MMT-8:β=-0.013,95%CI -0.022至-0.004;标准化β=-0.155,P=0.006),但波动绝对影响极小。
  • 25%患者维持持续不一致,表现为高主观疼痛 despite 肌酶正常化。

关键数值与推荐

  • 不一致定义为患者与医生全球评估(0-10 cm量表)差值≥±1 cm。
  • 基线临床显著不一致发生率为19.3%,正向不一致为16.8%。
  • 基线正向不一致预测1年HAQ较差(P=0.034)。
  • MMT-8与不一致关联:β=-0.013(95%CI -0.022至-0.004),标准化β=-0.155,P=0.006。
  • 疼痛中介不一致驱动功能残疾的比例为32.1%(P<0.001)。

临床怎么用

  • 应将患者报告结局(PRO)纳入常规临床监测。
  • 对存在正向不一致的患者,需早期针对性疼痛干预。
  • 持续不一致且肌酶正常化但高疼痛的患者亚群需特别关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Discordance between patient and physician perspectives on disease activity in idiopathic inflammatory myopathies (IIM) can compromise treatment outcomes. This study aimed to characterize patterns of discordance and distinct longitudinal trajectories in the MyoCite IIM cohort. METHODS: Discordance was defined as a difference between patient (PGA) and physician (PhGA) global assessments (0-10 cm scale) of ≥ ±1 cm. Prevalence was assessed at baseline (n = 244) and longitudinally at 6, 12 and 24 months (n = 128). Linear mixed-effects (n = 191) and bidirectional mediation models identified independent drivers and causal pathways. RESULTS: Clinically significant baseline discordance occurred in 19.3% of patients, predominantly manifesting as positive discordance (PGA > PhGA; 16.8%) across IIM subtypes (DM, PM, overlap myositis, anti-synthetase syndrome). Over 24 months, discordance narrowed with treatment. Baseline positive discordance strongly predicted poorer functional capacity (HAQ) at 1 year (P = 0.034). While objective muscle weakness statistically drove the gap (MMT-8: β = -0.013, 95% CI -0.022 to -0.004; standardized β = -0.155, P = 0.006), fluctuations had minimal absolute impact. A distinct subset (25%) maintained persistent discordance, exhibiting high subjective pain despite normalized muscle enzymes. Bidirectional mediation analysis revealed discordance unidirectionally drives future functional disability through unmanaged pain (32.1% mediated, P < 0.001) while reverse mediation (HAQ driving discordance via pain) was not statistically significant. CONCLUSION: Patient-physician discordance in IIM is an active, upstream driver of future functional loss, mediated significantly by pain, rather than a mere reflection of existing objective damage. It serves as a critical marker requiring early targeted pain intervention and integration of patient-reported outcomes into routine clinical monitoring.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Minikumari Rahulan L, Maroufy V, Agarwal V, et al. Patient-physician discordance in idiopathic inflammatory myopathies: a longitudinal analysis of links to disease activity and damage. Rheumatology (Oxford). 2026. PMID: 42266055. doi:10.1093/rheumatology/keag298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。